Teva Pharmaceutical Industries Limited (NYSE:TEVA) Receives $13.78 Consensus Price Target from Analysts

Teva Pharmaceutical Industries Limited (NYSE:TEVAGet Free Report) has earned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the firm, MarketBeat reports. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $13.78.

Several research firms have recently commented on TEVA. UBS Group raised shares of Teva Pharmaceutical Industries from a “neutral” rating to a “buy” rating and upped their price objective for the company from $11.00 to $13.00 in a report on Monday, November 27th. StockNews.com upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 1st. Piper Sandler upgraded Teva Pharmaceutical Industries from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $12.00 to $19.00 in a report on Monday, February 12th. JPMorgan Chase & Co. raised Teva Pharmaceutical Industries from an “underweight” rating to a “neutral” rating and set a $14.00 price target on the stock in a research note on Friday, March 8th. Finally, Barclays lifted their price target on Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “overweight” rating in a research report on Monday, February 5th.

Check Out Our Latest Stock Analysis on Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Trading Up 2.0 %

Shares of TEVA stock opened at $13.75 on Tuesday. The company has a current ratio of 1.02, a quick ratio of 0.69 and a debt-to-equity ratio of 2.23. Teva Pharmaceutical Industries has a 1 year low of $7.09 and a 1 year high of $13.93. The stock has a market cap of $15.41 billion, a P/E ratio of -29.26, a price-to-earnings-growth ratio of 1.54 and a beta of 1.04. The stock has a 50 day simple moving average of $12.66 and a 200 day simple moving average of $10.72.

Teva Pharmaceutical Industries (NYSE:TEVAGet Free Report) last posted its quarterly earnings data on Wednesday, January 31st. The company reported $0.98 EPS for the quarter, topping the consensus estimate of $0.73 by $0.25. The business had revenue of $4.46 billion for the quarter, compared to analyst estimates of $3.97 billion. Teva Pharmaceutical Industries had a negative net margin of 3.33% and a positive return on equity of 34.90%. On average, research analysts predict that Teva Pharmaceutical Industries will post 2.28 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Mark Sabag sold 100,000 shares of the business’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total transaction of $1,352,000.00. Following the transaction, the executive vice president now directly owns 382,590 shares in the company, valued at $5,172,616.80. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Mark Sabag sold 100,000 shares of the stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $13.52, for a total value of $1,352,000.00. Following the completion of the transaction, the executive vice president now owns 382,590 shares in the company, valued at approximately $5,172,616.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Richard D. Francis sold 74,530 shares of the firm’s stock in a transaction dated Thursday, February 15th. The stock was sold at an average price of $13.15, for a total transaction of $980,069.50. Following the sale, the chief executive officer now directly owns 87,125 shares in the company, valued at $1,145,693.75. The disclosure for this sale can be found here. Over the last quarter, insiders sold 390,738 shares of company stock valued at $5,132,766. Insiders own 0.62% of the company’s stock.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

Hedge funds have recently added to or reduced their stakes in the business. Money Concepts Capital Corp acquired a new position in Teva Pharmaceutical Industries in the fourth quarter worth approximately $25,000. Quilter Plc bought a new stake in Teva Pharmaceutical Industries in the 1st quarter valued at approximately $3,103,125,000. Tower Research Capital LLC TRC increased its position in shares of Teva Pharmaceutical Industries by 1,729.5% during the 3rd quarter. Tower Research Capital LLC TRC now owns 3,787 shares of the company’s stock worth $39,000 after purchasing an additional 3,580 shares during the last quarter. US Bancorp DE increased its holdings in shares of Teva Pharmaceutical Industries by 36.5% during the 4th quarter. US Bancorp DE now owns 3,828 shares of the company’s stock worth $40,000 after acquiring an additional 1,023 shares during the last quarter. Finally, Blue Trust Inc. grew its holdings in Teva Pharmaceutical Industries by 92.3% in the 4th quarter. Blue Trust Inc. now owns 4,541 shares of the company’s stock valued at $46,000 after buying an additional 2,180 shares in the last quarter. Institutional investors and hedge funds own 43.23% of the company’s stock.

About Teva Pharmaceutical Industries

(Get Free Report

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

Featured Stories

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.